The Usefulness of Commercially Available Serological Tests in the Diagnosis and Monitoring of Treatment in Patients with Alveolar Echinococcosis

Overview

Journal Clin Exp Hepatol

Specialty Gastroenterology

Date 2020 Jan 2

PMID 31893245

Citations 5

Authors

Malgorzata Sulima

Beata Szostakowska

Waclaw Nahorski

Katarzyna Sikorska

Wojciech Wolyniec

Piotr Waz

Affiliations

Soon will be listed here.

Abstract

Aim Of The Study: To assess the clinical usefulness of serological tests in the diagnosis and monitoring of treatment of patients with alveolar echinococcosis (AE).

Material And Methods: The results of serological tests, i.e. Echinococcus multilocularis ELISA (Bordier Affinity Products) and Echinococcus Western Blot IgG (LDBIO Diagnostic), of 66 patients were analysed. Duration of follow-up was two years after diagnosis. In the second phase of the study 11 sera obtained from the patients undergoing surgical treatment, in whom the results of Echinococcus Western Blot IgG assay were still positive, were additionally tested with Anti-Echinococcus EUROLINE-WB (IgG) assay.

Results: Statistically significant negativization of the Echinococcus multilocularis ELISA test was observed in the group of patients who underwent radical surgery or liver transplantation. Negativization of Echinococcus Western Blot IgG assay results was observed in some patients, among both those who received conservative treatment and those who underwent surgery, but no statistically significant differences were found between treatment groups. In 54.5% of cases the Anti-Echinococcus EUROLINE-WB (IgG) test result was negative when the results of the Echinococcus Western Blot IgG assay were still positive.

Conclusions: Echinococcus multilocularis ELISA proved to be useful in assessing the activity of AE in a group of patients who underwent radical surgery or liver transplantation. The results of our study suggest that Anti-Echinococcus EUROLINE-WB (IgG) is a more dynamic test, which at the time of disappearance of AE activity becomes negative earlier.

Citing Articles

18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting.

Eberhardt N, Peters L, Kapp-Schwoerer S, Beer M, Beer A, Gruner B Pathogens. 2022; 11(3).

PMID: 35335672 PMC: 8951377. DOI: 10.3390/pathogens11030348.

Evaluation of Serological Markers in Alveolar Echinococcosis Emphasizing the Correlation of PET-CTI Tracer Uptake with RecEm18 and -Specific IgG.

Hotz J, Peters L, Kapp-Schworer S, Theis F, Eberhardt N, Essig A Pathogens. 2022; 11(2).

PMID: 35215182 PMC: 8880252. DOI: 10.3390/pathogens11020239.

Membrane Technology for Rapid Point-of-Care Diagnostics for Parasitic Neglected Tropical Diseases.

Rogers M, McManus D, Muhi S, Gordon C Clin Microbiol Rev. 2021; 34(4):e0032920.

PMID: 34378956 PMC: 8404699. DOI: 10.1128/CMR.00329-20.

Dual Role of Hepatic Macrophages in the Establishment of the Metacestode in Mice.

Wang H, Zhang C, Fang B, Hou J, Li W, Li Z Front Immunol. 2021; 11:600635.

PMID: 33488594 PMC: 7820908. DOI: 10.3389/fimmu.2020.600635.

Portal hypertension as a result of the incomplete surgically treated advanced alveolar echinococcosis: a case description.

Pielok L, Karczewski M, Cierach W, Zmora P, Lenartowicz E, Stefaniak J BMC Gastroenterol. 2020; 20(1):176.

PMID: 32503447 PMC: 7275433. DOI: 10.1186/s12876-020-01320-0.

References

Ito A, Xiao N, Liance M, Sato M, Sako Y, Mamuti W . Evaluation of an enzyme-linked immunosorbent assay (ELISA) with affinity-purified Em18 and an ELISA with recombinant Em18 for differential diagnosis of alveolar echinococcosis: results of a blind test. J Clin Microbiol. 2002; 40(11):4161-5. PMC: 139688. DOI: 10.1128/JCM.40.11.4161-4165.2002. View

Nahorski W, Knap J, Pawlowski Z, Krawczyk M, Polanski J, Stefaniak J . Human alveolar echinococcosis in Poland: 1990-2011. PLoS Negl Trop Dis. 2013; 7(1):e1986. PMC: 3536814. DOI: 10.1371/journal.pntd.0001986. View

McManus D, Zhang W, Li J, Bartley P . Echinococcosis. Lancet. 2003; 362(9392):1295-304. DOI: 10.1016/S0140-6736(03)14573-4. View

Paul M, Stefaniak J, Rychlicki W, Kacprzak E, Mazur-Roszak M, Komarnicki M . [Evaluation of a risk of a cross-reactivity with Echinococcus multilocularis-specific Em2plus antigen in patients with liver cancer]. Wiad Parazytol. 2006; 50(3):439-45. View

Graeter T, Kratzer W, Oeztuerk S, Haenle M, Mason R, Hillenbrand A . Proposal of a computed tomography classification for hepatic alveolar echinococcosis. World J Gastroenterol. 2016; 22(13):3621-31. PMC: 4814648. DOI: 10.3748/wjg.v22.i13.3621. View

Coskun A, Ozturk M, Karahan O, Erdogan N, Isin S, Gulec M . Alveolar echinococcosis of the liver: correlative color Doppler US, CT, and MRI study. Acta Radiol. 2004; 45(5):492-8. DOI: 10.1080/02841850410005912. View

Liance M, Janin V, Bresson-Hadni S, Vuitton D, Houin R, Piarroux R . Immunodiagnosis of Echinococcus infections: confirmatory testing and species differentiation by a new commercial Western Blot. J Clin Microbiol. 2000; 38(10):3718-21. PMC: 87463. DOI: 10.1128/JCM.38.10.3718-3721.2000. View

Ma L, Ito A, Liu Y, Wang X, Yao Y, Yu D . Alveolar echinococcosis: Em2plus-ELISA and Em18-western blots for follow-up after treatment with albendazole. Trans R Soc Trop Med Hyg. 1997; 91(4):476-8. DOI: 10.1016/s0035-9203(97)90291-1. View

Gottstein B, Jacquier P, Bresson-Hadni S, Eckert J . Improved primary immunodiagnosis of alveolar echinococcosis in humans by an enzyme-linked immunosorbent assay using the Em2plus antigen. J Clin Microbiol. 1993; 31(2):373-6. PMC: 262768. DOI: 10.1128/jcm.31.2.373-376.1993. View

10.

Ammann R, Renner E, Gottstein B, Grimm F, Eckert J, Renner E . Immunosurveillance of alveolar echinococcosis by specific humoral and cellular immune tests: long-term analysis of the Swiss chemotherapy trial (1976-2001). J Hepatol. 2004; 41(4):551-9. DOI: 10.1016/j.jhep.2004.06.015. View

11.

Bresson-Hadni S, Laplante J, Lenys D, Rohmer P, Gottstein B, Jacquier P . Seroepidemiologic screening of Echinococcus multilocularis infection in a European area endemic for alveolar echinococcosis. Am J Trop Med Hyg. 1994; 51(6):837-46. DOI: 10.4269/ajtmh.1994.51.837. View

12.

Ito A, Sako Y, Yamasaki H, Mamuti W, Nakaya K, Nakao M . Development of Em18-immunoblot and Em18-ELISA for specific diagnosis of alveolar echinococcosis. Acta Trop. 2003; 85(2):173-82. DOI: 10.1016/s0001-706x(02)00221-8. View

13.

Tappe D, Gruner B, Kern P, Frosch M . Evaluation of a commercial Echinococcus Western Blot assay for serological follow-up of patients with alveolar echinococcosis. Clin Vaccine Immunol. 2008; 15(11):1633-7. PMC: 2583513. DOI: 10.1128/CVI.00272-08. View

14.

Ishikawa Y, Sako Y, Itoh S, Ohtake T, Kohgo Y, Matsuno T . Serological monitoring of progression of alveolar echinococcosis with multiorgan involvement by use of recombinant Em18. J Clin Microbiol. 2009; 47(10):3191-6. PMC: 2756934. DOI: 10.1128/JCM.01111-09. View

15.

Brunetti E, Kern P, Vuitton D . Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2009; 114(1):1-16. DOI: 10.1016/j.actatropica.2009.11.001. View

16.

Sato N, Namieno T, Furuya K, Takahashi H, Yamashita K, Uchino J . Contribution of mass screening system to resectability of hepatic lesions involving Echinococcus multilocularis. J Gastroenterol. 1997; 32(3):351-4. DOI: 10.1007/BF02934492. View

17.

Knapp J, Sako Y, Grenouillet F, Bresson-Hadni S, Richou C, Gbaguidi-Haore H . Comparison of the serological tests ICT and ELISA for the diagnosis of alveolar echinococcosis in France. Parasite. 2014; 21:34. PMC: 4111071. DOI: 10.1051/parasite/2014037. View

18.

Fujimoto Y, Ito A, Ishikawa Y, Inoue M, Suzuki Y, Ohhira M . Usefulness of recombinant Em18-ELISA to evaluate efficacy of treatment in patients with alveolar echinococcosis. J Gastroenterol. 2005; 40(4):426-31. DOI: 10.1007/s00535-004-1559-7. View

19.

Gottstein B, Tschudi K, Eckert J, Ammann R . Em2-ELISA for the follow-up of alveolar echinococcosis after complete surgical resection of liver lesions. Trans R Soc Trop Med Hyg. 1989; 83(3):389-93. DOI: 10.1016/0035-9203(89)90512-9. View